SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic therapies in patients with type 2 diabetes mellitus and are associated with improved glycaemic control as well as with reductions in body mass and blood pressure. In large cardiovascular outcome trials in patients with diabetes, SGLT2 inhibitors improve cardiovascular and...
Alternative Titles
Full title
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2424096841
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2424096841
Other Identifiers
ISSN
1759-5002
E-ISSN
1759-5010
DOI
10.1038/s41569-020-0406-8
